Haqq Christopher 4

What Happened
Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics (ELTX), received an equity award on July 16, 2026 covering 64,643 shares. The reported acquisition price is $0.00 because this was an option/award (derivative), not a market purchase or sale. No shares were sold or exercised in this transaction.

Key Details

• Transaction date: 2026-07-16 (Form 4 filed 2026-07-17).
• Transaction type/code: Award/Grant (derivative) — reported as "A".
• Amount: 64,643 shares (stock option grant) at $0.00 reported price.
• Vesting: 50% vests on July 16, 2027 and the remaining 50% vests on July 16, 2028, subject to continued service (per filing footnote).
• Shares owned after transaction: not specified in the information provided in this summary.
• Timeliness: filing appears timely (reported period 7/16/2026, filed 7/17/2026).

Context
This was a grant of options/awards that vest over two years — a common executive compensation/retention tool. Because it’s a derivative grant (not an open-market purchase or sale), it does not represent an immediate cash outlay or a direct buy/sell signal; future vesting and any exercise would be separate events disclosed later.